Oncology
META ANALYSIS
● Meta-analysis
For advanced nasopharyngeal cancer, can immune therapy help? New analysis shows what patients might expect.
New England Journal of Medicine
Published March 30, 2026
Bai Weiliang, Xu Shengqun, Miao Lei, Zhao Jingying, Zhao Lijun, Gao Zhao, Liu Tiancong
For people with recurrent or metastatic nasopharyngeal cancer (NPC), a cancer that starts in the upper throat, finding effective treatments is critical. A new analysis pooled data from 883 patients across nine studies to understand what happens when they receive a type of drug called a PD-1/PD-L1 inhibitor. These drugs, known as immune checkpoint inhibitors, work by helping the body's own immune system fight the cancer.
The analysis found that, on average, patients lived without their cancer getting worse for about 4.2 months. They lived for about 16.3 months overall. Looking at one-year milestones, about 43% of patients were alive without their cancer progressing, and 80% were still alive. The treatment shrank the cancer in about 45% of patients and controlled it (either shrinking or stopping its growth) in about 65%.
However, side effects were very common. About 90% of patients experienced some side effect, and serious side effects (grade 3 or higher) happened in about 34% of patients. The analysis concludes that while this summarizes the current evidence on how well these drugs work and their safety, more high-quality randomized trials are needed to confirm their role.
View Original Abstract ↓
BACKGROUND: Nasopharyngeal carcinoma (NPC) has a poor prognosis, largely due to immune escape. The programmed cell death protein 1 (PD-1) receptor and its ligand, PD-L1, play critical roles in this immune evasion. Consequently, blocking the PD-1/PD-L1 pathway with immune checkpoint inhibitors has become an established therapeutic strategy.
METHODS: We performed a systematic literature search of PubMed, Embase, and the Cochrane Library for studies published up to November 14, 2024, investigating PD-1/PD-L1 inhibitors in recurrent or metastatic NPC. The analyzed outcomes included progression-free survival (PFS), overall survival (OS), 1-year PFS rate, 1-year OS rate, objective response rate, disease control rate, and adverse events (AEs).
RESULTS: Nine studies (comprising 10 datasets with 883 NPC patients) were included, consisting of 2 randomized controlled trials (RCTs) and 7 single-arm studies. The pooled analysis demonstrated a median PFS of 4.21 months (95% confidence interval [CI]: 2.47-5.95; P = .000; I2 = 78.5%) and a median OS of 16.27 months (95% CI: 14.60-17.94; P = .000; I2 = 0%). The pooled 1-year PFS rate was 43% (95% CI: 14%-73%; P = .004; I2 = 99.1%), and the 1-year OS rate was 80% (95% CI: 70%-91%; P = .000; I2 = 82.0%). The objective response rate was 45% (95% CI: 25%-64%; P = .000; I2 = 96.8%), and the disease control rate was 65% (95% CI: 48%-82%; P = .000; I2 = 96.4%). The incidence of any-grade AEs was 90% (95% CI: 74%-99%; P = .000; I2 = 94.1%), while grade ≥3 AEs occurred in 34% of patients (95% CI: 12%-61%; P < .001; I2 = 95.2%). No significant publication bias was identified.
CONCLUSION: This meta-analysis summarizes the efficacy and safety profile of PD-1/PD-L1 inhibitors in recurrent or metastatic NPC. The findings highlight the need for additional randomized controlled trials to further validate the role of these therapies and provide an updated reference for clinical practice.